Results 21 to 30 of about 9,061 (176)

The Histopathology of Abemaciclib-Induced Interstitial Lung Disease: A First Case Report With Transbronchial Lung Cryobiopsy

Breast Cancer: Basic and Clinical Research
Abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, is crucial in treating hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic or recurrent breast cancer.
Shota Kaburaki, Toru Tanaka, Akari Murata, Koichiro Kamio, Yosuke Tanaka, Yasuhiro Terasaki, Kazuo Kasahara, Masahiro Seike   +7 more
doaj   +2 more sources

Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China [PDF]

BMC Cancer
Background CDK4/6 inhibitors combined with endocrine therapy constitute the global first-line standard of care for HR + /HER2 − advanced breast cancer (ABC), yet no head-to-head trials comparing different CDK4/6 inhibitors have been conducted, and real ...
Xianan Guo, Panni Li, Shiyao Hu, Yuqin Ding, Bojian Xie, Yangjun Cai, Huihui Chen, Xiawei Li, Shiwei Guo, Yanyan Wang, Yunxiang Zhou, Yiding Chen   +11 more
doaj   +2 more sources

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

Frontiers in Oncology
BackgroundThe oral, selective, and potent small molecule cyclin-dependent kinases (CDK) 4/6 inhibitor (CDK4/6i) abemaciclib has demonstrated efficacy in advanced breast cancer and high-risk early breast cancer.
Sara M. Tolaney, Komal Jhaveri, Teresa Helsten, Shannon L. Puhalla, Alison Conlin, E. Claire Dees, Muralidhar Beeram, Sonya C. Chapman, Andrew Lithio, Lacey M. Litchfield, Matthew P. Goetz   +10 more
doaj   +2 more sources

PROCESS FOR PURIFICATION OF ABEMACICLIB [PDF]

The present application relates to a process for purification of ...
Anonymous,
core   +4 more sources

Image2_Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells.tif

, 2022
Abemaciclib is a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor approved for the treatment of metastatic breast cancer. Preclinical studies suggest that abemaciclib has the potential for lung cancer treatment.
Cun-Wu Chen (12910838), Milton Talukder (5950043), Chao-Yue Sun (5392448), Di Cao (839887)   +3 more
core   +1 more source

In vivo efficacy of Abemaciclib and Cetuximab in SF8894 chordoma xenograft model_CF41

, 2021
DrugTargetsAbemaciclib + CetuximabCDK4/6 + EGFRDose50mg/kg (Abemaciclib) 20mg/kg (Cetuximab)RoutePO (Abemaciclib) IP (Cetuximab)Scheduleqd to end (Abemaciclib) 2xwklyx6 (Cetuximab) Duration of treatment42 dStrain of miceAthymic NudeTGI (day)49% (Day 41)p-
Dan Freed (4391989)
core   +1 more source

Image3_Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells.tif

, 2022
Abemaciclib is a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor approved for the treatment of metastatic breast cancer. Preclinical studies suggest that abemaciclib has the potential for lung cancer treatment.
Cun-Wu Chen (12910838), Milton Talukder (5950043), Chao-Yue Sun (5392448), Di Cao (839887)   +3 more
core   +1 more source

In vivo efficacy of Abemaciclib and Cetuximab in CF555 chordoma xenograft model_CF40

, 2021
DrugTargetsAbemaciclib + CetuximabCDK4/6 + EGFRDose50mg/kg (Abemaciclib) 20mg/kg (Cetuximab)RoutePO (Abemaciclib) IP (Cetuximab)Scheduleqd to end (Abemaciclib) 2xwklyx6 (Cetuximab) Duration of treatment42 dStrain of miceAthymic NudeTGI (day)93% (Day 42)p-
Dan Freed (4391989)
core   +1 more source

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

, 2017
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...
손주혁
core   +2 more sources

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

Therapeutic Advances in Medical Oncology, 2020
Aim: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer
Qing Yuan Zhang, Tao Sun, Yong Mei Yin, Hui Ping Li, Min Yan, Zhong Sheng Tong, Christina P. Oppermann, Yun Peng Liu, Romulo Costa, Man Li, Ying Cheng, Qu Chang Ouyang, Xi Chen, Ning Liao, Xin Hong Wu, Xiao Jia Wang, Ji Feng Feng, Roberto Hegg, G.B. Kanakasetty, Maria A. Coccia-Portugal, Ru Bing Han, Yi Lu, Hai Dong Chi, Ze Fei Jiang, Xi Chun Hu   +24 more
doaj   +1 more source